Tocilizumab alleviates cytokine storm with acute respiratory distress syndrome in severe <scp>SARS‐CoV</scp>‐2 infection in Taiwan

Chen, Yen-Wen; Liao, Hsien Tzung

doi:10.1111/imj.15335

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tocilizumab is a recombinant humanized anti-IL-6 receptor mAb approved for patients with rheumatologic disorders such as giant cell arteritis and rheumatoid arthritis as well as cytokine release syndrome induced by chimeric antigen receptor T cell (CAR T-cell) therapy [ 23 ]. Given the finding that many patients with severe COVID-19 demonstrate signs of cytokine release syndrome, there has been intense interest in using this drug in patients hospitalized with COVID-19 [ 24 ].…”

Section: Immunomodulators For Hospitalized Patientsmentioning

confidence: 99%

Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)

McCarthy

2022

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction SARS-CoV-2, the virus that causes COVID-19, elicits a variety of host responses ranging from asymptomatic or mild illness in most people, to severe disease and critical illness in a subset of patients with systemic inflammation and hypoxemic respiratory failure. Areas Covered Heterogeneous clinical presentations are often driven by disparate responses of the host immune system, with severe disease associated with aberrant interferon signaling or cytokine storm syndrome. This manuscript examines current therapeutic approaches, including the use of immunomodulators such as corticosteroids, interleukin inhibitors, kinase inhibitors, fluvoxamine, and ivermectin, and also explores the ways that these therapies and others may be used to treat COVID-19 in the future. Expert opinion Modulation of the immune response has become a mainstay of treatment of COVID-19, although the optimal mechanism has not yet been defined and there is considerable controversy regarding clinical management. As time progresses, the therapeutic approach to COVID-19 will undoubtedly change, particularly as we learn more about the pathophysiology of SARS-CoV-2 infection.

show abstract

Section: Immunomodulators For Hospitalized Patientsmentioning

confidence: 99%